novel
refer
also
swine
flu
well
viral
agent
involv
common
cold
infect
compos
public
health
problem
account
mani
visit
primari
secondari
health
care
servic
hospit
admiss
addit
consider
number
death
likewis
document
especi
vulner
peopl
infect
easili
transmit
exposur
infect
droplet
expel
cough
sneez
inhal
contamin
hand
surfac
symptom
includ
fever
cough
headach
muscl
joint
pain
sore
throat
runni
nose
sometim
vomit
diarrhea
new
influenza
appear
contagi
season
influenza
spread
rapidli
particularli
amongst
young
peopl
sever
diseas
rang
mild
symptom
seriou
ill
occasion
even
death
major
peopl
contract
viru
experi
mild
diseas
recov
without
antivir
treatment
medic
care
addit
seriou
hospit
case
underli
health
condit
impair
immun
function
antivir
drug
may
reduc
symptom
durat
ill
may
also
contribut
prevent
sever
diseas
death
howev
effect
cost
administ
therapi
remain
interest
topic
investig
recent
cochran
metaanalysi
although
contest
report
limit
effect
oseltamivir
tamiflu
classic
antivir
drug
jefferson
et
al
mainli
relat
timelimit
usual
selfheal
natur
diseas
much
discuss
dedic
use
herbal
medicin
common
cold
randomis
control
trial
rct
report
effect
socheougryongtang
ko
et
al
yeongyopaedoksan
common
cold
byun
et
al
use
herb
ailment
island
crete
mention
sinc
bronz
age
arnott
herbal
medicin
also
long
histori
ancient
greec
popular
medic
handbook
byzantin
era
forward
incorpor
materi
root
ancient
medicin
routin
claim
hippocr
galen
among
other
sourc
clark
current
time
antioxid
activ
herb
rural
crete
investig
shown
herbal
extract
decreas
lipid
peroxid
cultur
lung
cell
expos
iron
ozon
lioni
et
al
previou
ethnobotan
field
studi
reveal
exist
indigen
knowledg
system
rural
crete
certain
combin
differ
aromat
plant
rural
area
crete
use
prevent
cure
common
cold
influenza
lioni
et
al
biolog
effect
bioactiv
essenti
oil
well
antibacteri
properti
report
literatur
cowan
burt
bakkali
et
al
koroch
et
al
similarli
antivir
potenti
medicin
plant
discuss
well
jassim
naji
mukhtar
et
al
also
excit
even
though
term
viru
recent
term
modern
medicin
silverstein
rural
societi
without
prior
knowledg
term
absenc
immunolog
knowledg
protect
popul
use
tradit
folkmedicin
state
interest
studi
extent
ethnopharmacolog
knowledg
evidencebas
effect
virusinduc
diseas
effort
also
taken
account
certain
cretan
histori
archeolog
element
well
ethnopharmacolog
use
eastern
mediterranean
near
east
region
suggest
benefici
action
combin
upper
respiratori
viral
infect
dafni
et
al
honda
et
al
lev
amar
said
et
al
hanlid
et
al
lardo
hudaib
et
al
state
studi
report
result
effect
extract
base
three
cretan
aromat
plant
reduct
durat
sever
symptom
patient
upper
respiratori
tract
infect
util
standard
questionnair
physic
examin
measur
decreas
inflamm
assay
creactiv
protein
crp
level
plant
materi
identifi
one
author
sp
voucher
specimen
three
speci
deposit
herbarium
tau
aristotl
univers
thessaloniki
formul
essenti
oil
extract
provid
author
prepar
olvo
sa
accord
patent
patent
applic
relat
subject
thyme
spanish
oregano
coridothymu
capitatu
l
rchb
f
synonym
thymbra
capitata
l
cav
dictamnu
cretan
dittani
origanum
dictamnu
l
sage
salvia
fruticosa
mill
salvia
pomifera
l
extract
steam
distil
analysi
essenti
oil
perform
ga
chromatographymass
spectroscopi
gcm
shimadzu
qp
apparatu
gc
equip
column
length
film
thick
mm
diamet
mm
max
useabl
temperatur
quadrupol
mass
spectromet
detector
column
temperatur
initi
min
gradual
increas
kept
min
final
increas
held
min
carrier
ga
helium
flow
rate
mlmin
use
inject
volum
sampl
measur
split
mode
procedur
split
ratio
injector
detector
maintain
respect
gsm
detect
electron
ioniz
system
use
ioniz
energi
ev
chemic
percentag
composit
specif
constitu
essenti
oil
adam
shown
supplement
tabl
essenti
oil
dilut
mll
extra
virgin
oliv
oil
use
vehicl
formul
ml
softgel
capsul
daili
dose
two
capsul
dose
base
anthropolog
report
fieldwork
work
studi
carri
crete
lioni
et
al
correspond
two
cup
infus
aforement
aromat
plant
placebo
capsul
contain
extravirgin
oil
equal
formul
ml
softgel
capsul
gcm
chemic
percentag
composit
formul
mixtur
adam
shown
supplement
tabl
particip
recruit
octob
februari
elig
subject
patient
age
year
older
present
local
health
centr
haraka
prefectur
heraklion
rural
crete
greec
symptom
upper
respiratori
tract
infect
initi
within
previou
h
jackson
criteria
use
order
identifi
patient
suffer
common
cold
jackson
et
al
criteria
consist
sneez
nasal
discharg
nasal
obstruct
sore
throat
cough
headach
malais
chilli
patient
consid
elig
particip
jackson
score
greater
equal
two
least
one
first
four
coldspecif
symptom
present
patient
daili
dosag
acetylsalicyl
acid
greater
mg
exclud
studi
criteria
exclus
presenc
malign
immunosuppress
pregnanc
haraka
health
center
serv
popul
rural
crete
gener
practition
gp
practic
centr
agre
particip
elig
patient
inform
studi
enrol
provid
written
consent
random
placebocontrol
doubleblind
parallel
group
design
use
consort
herbal
medicin
intervent
guidelin
follow
gagnier
et
al
stratifi
random
use
vari
block
size
implement
use
statist
environ
r
version
packag
blockrand
stratif
sex
age
cutoff
taken
year
packag
contain
capsul
store
health
centr
ident
appear
differ
id
label
correspond
specif
patient
enrol
patient
receiv
either
cretan
aromat
plant
product
placebo
gp
patient
blind
treatment
group
studi
coordin
clinic
chemistri
immunolog
diagnost
laboratori
particip
personnel
patient
examin
gp
offic
day
present
followup
day
later
contact
telephon
daili
basi
gp
initi
final
visit
complet
daili
questionnair
see
section
studi
receiv
approv
commiss
bioethic
univers
gener
hospit
heraklion
written
fulli
inform
consent
obtain
patient
enrol
studi
trial
regist
intern
standard
randomis
control
trial
number
regist
www
isrctn
number
appropri
permiss
valid
wisconsin
upper
respiratori
system
survey
instrument
translat
greek
use
quantifi
symptom
sever
durat
barrett
et
al
evalu
illnessspecif
qualiti
life
instrument
design
assess
neg
impact
acut
upper
respiratori
infect
daili
wurss
summari
score
calcul
sum
score
individu
item
first
last
item
includ
summat
categor
differ
refer
domain
wwwfammedwiscedu
access
august
higher
score
indic
sever
symptom
theoret
maximum
score
whilst
score
indic
complet
absenc
symptom
questionnair
complet
daili
basi
seven
time
total
initi
day
one
final
followup
day
seven
complet
patient
gp
offic
complet
undertaken
gp
use
telephon
interview
initi
visit
inform
also
obtain
particip
gender
date
birth
selfreport
weight
height
smoke
histori
number
cigarett
per
day
year
smoke
year
start
year
quit
alcohol
consumpt
type
drink
milligram
per
day
medic
histori
chronic
ill
type
drug
provid
drug
dosag
vaccin
streptococcu
pneumonia
influenza
hospit
histori
subject
underw
clinic
examin
includ
follow
systol
blood
pressur
sbp
mmhg
diastol
blood
pressur
dbp
mmhg
satur
puls
beat
per
minut
bodi
temperatur
degre
celsiu
respiratori
rate
breath
per
minut
measur
repeat
day
followup
visit
gp
offic
blood
drawn
day
one
seven
follow
test
erythrocyt
count
rbc
hemoglobin
gdl
hematocrit
white
blood
cell
count
wbc
l
neutrophil
lymphocyt
monocyt
thrombocyt
alanin
aminotransferas
alat
sgpt
ul
aspart
aminotransferas
asat
sgot
ul
alkalin
phosphatas
alp
ul
creatinin
mgdl
creactiv
protein
crp
mgdl
assay
perform
univers
hospit
heraklion
specif
agreement
routin
standard
method
number
protocol
realtim
pcr
assay
dnarna
extract
nucleic
acid
extract
nasopharyng
swab
use
commerci
purif
kit
purelink
viral
dnarna
kit
invitrogen
suitabl
viral
dnarna
extract
accord
manufactur
instruct
sampl
quantifi
spectrophotometr
normal
aliquot
produc
sampl
dnarna
isol
perform
separ
area
laboratori
distant
polymeras
chain
reaction
pcr
area
meticul
care
taken
avoid
crosscontamin
dnarna
one
hundr
swab
taken
six
swab
use
intern
control
result
avail
sampl
detect
respiratori
virus
carri
use
two
commerci
kit
real
time
pcr
first
kit
allow
multiplex
realtim
pcr
detect
identif
human
respiratori
virus
name
human
respiratori
syncyti
viru
hrsv
rna
human
metapneumoviru
hmpv
rna
human
parainfluenza
hpiv
rna
hkui
human
coronaviru
hcov
rna
human
rhinoviru
hrv
rna
human
b
c
e
adenoviru
hadv
dna
well
human
bocaviru
hbov
dna
cat
sacacc
addit
second
commerci
kit
also
employ
simultan
detect
pandem
influenza
viru
influenza
b
viru
fluab
type
realtim
detect
seegen
realtim
pcr
reaction
set
accord
manufactur
protocol
follow
amplif
condit
recommend
data
collect
anneal
two
measur
time
melt
curv
analysi
experi
conduct
abi
fast
system
realtim
pcr
thermal
cycler
use
softwar
version
appli
biosystem
qualiti
control
dnarna
sampl
accomplish
check
success
amplif
gene
primari
outcom
interest
durat
symptom
chang
sever
symptom
studi
period
durat
symptom
assess
number
day
enrol
particip
report
sick
question
sick
feel
today
ie
respons
likert
scale
symptom
sever
assess
outcom
questionnair
secondari
outcom
interest
normal
mgdl
crp
posit
subject
day
number
need
treat
nnt
indic
number
patient
need
treat
benefit
one
also
calcul
order
measur
studi
effect
overal
sampl
size
group
calcul
necessari
detect
mediumlarg
effect
size
power
signific
level
comparison
mean
use
gpower
faul
et
al
gener
characterist
patient
group
baselin
summar
use
descript
statist
univari
comparison
patient
characterist
two
studi
group
perform
use
pearson
chisquar
test
independ
categor
data
independ
sampl
ttest
normal
distribut
variabl
nonparametr
mannwhitney
test
normal
distribut
variabl
sever
symptom
studi
period
compar
intervent
control
group
use
score
univari
techniqu
multipl
linear
regress
model
adjust
age
sex
initi
crp
level
bodi
mass
index
bmi
presenc
chronic
diseas
sever
assess
three
way
firstli
averag
total
score
time
period
compar
group
ie
sum
daili
score
b
differ
group
assess
calcul
area
timesever
curv
yaxi
score
area
curv
auc
calcul
use
trapezoid
approxim
c
final
averag
maximum
wurss
score
subject
compar
group
percentag
miss
valu
daili
score
rang
baselin
day
three
confid
interv
median
daili
score
calcul
use
binomi
method
centil
command
stata
multipl
linear
regress
model
appli
depend
variabl
natur
logarithm
auc
ln
auc
independ
variabl
treatment
interventionplacebo
age
year
bmi
kgm
gender
malefemal
presenc
chronic
ill
yesno
crplevel
upon
present
mgdl
vs
mgdl
discretetim
surviv
analysi
use
assess
possibl
differ
time
symptom
cessat
ie
symptom
durat
group
symptom
consid
absent
first
day
wurss
score
drop
zero
intentiontotreat
approach
use
complementari
loglog
model
discret
time
proport
hazard
model
also
appli
data
model
estim
maximum
likelihood
adjust
age
sex
stata
command
cloglog
proport
initi
crpposit
subject
crpneg
end
studi
compar
group
addit
withingroup
comparison
crp
chang
made
use
mcnemar
test
random
diagnos
upper
respiratori
tract
infect
presum
viral
etiolog
respiratori
virus
detect
howev
patient
test
statist
method
describ
initi
appli
total
sampl
analys
subsequ
repeat
use
data
subsampl
virusposit
patient
signific
level
set
statist
softwar
use
spss
version
univari
analysi
stata
version
surviv
analysi
result
present
outcom
complet
sampl
sampl
virusposit
patient
total
patient
sign
andor
symptom
upper
respiratori
tract
infect
visit
health
centr
charaka
month
timeperiod
femal
male
one
hundr
thirti
five
meet
elig
criteria
femal
male
subject
present
doctor
h
symptom
begun
reason
exclus
includ
pregnanc
treatment
acetylsalicyl
acid
daili
dose
mg
malign
immunosuppress
fiftyfour
elig
patient
agre
particip
studi
common
reason
state
lack
timein
followup
four
patient
will
particip
clinic
trial
fourteen
patient
provid
detail
deni
variou
reason
comparison
patient
will
particip
produc
signific
result
term
gender
distribut
will
particip
significantli
older
mean
age
versu
year
ci
differ
year
one
hundr
eight
patient
enrol
studi
howev
three
patient
complet
two
placebo
group
one
intervent
group
one
patient
develop
pneumonia
one
patient
report
unabl
swallow
pill
one
patient
lost
followup
initi
examin
fig
intervent
control
group
patient
similar
demograph
characterist
gender
age
bmi
smoke
habit
alcohol
consumpt
vaccin
pattern
streptococcu
pneumonia
influenza
supplement
tabl
group
half
patient
report
suffer
least
one
chronic
ill
frequent
chronic
ill
heart
diseas
metabol
diseas
follow
respiratori
musculoskelet
diseas
clinic
examin
characterist
includ
systol
diastol
blood
pressur
oxygen
satur
puls
per
minut
respiratori
rate
temperatur
also
similar
group
supplement
tabl
final
hematolog
rbc
hemoglobin
hematocrit
wbc
neutrophil
lymphocyt
monocyt
thrombocyt
biochem
sgpt
sgot
alp
creatinin
immunolog
crp
paramet
similar
group
patient
supplement
tabl
median
lymphocyt
count
increas
either
group
suggest
initi
phase
respiratori
infect
median
score
baselin
lower
quartil
q
upper
quartil
q
placebo
group
q
q
intervent
group
supplement
tabl
one
miss
bmi
measur
two
miss
valu
packyear
smoke
one
pneumococc
vaccin
two
regard
previou
hospit
patient
miss
measur
regard
presenc
chronic
diseas
vaccin
influenza
alcohol
consumpt
forti
eight
patient
test
found
posit
least
one
viral
strain
fig
assay
specif
rtqpcr
distribut
demograph
hematolog
biochem
variabl
appear
similar
analysi
restrict
virusposit
patient
supplement
tabl
possibl
except
except
lymphocyt
count
appear
somewhat
higher
baselin
intervent
group
interestingli
posit
patient
human
rhinoviru
hrv
detect
intervent
group
control
group
influenza
human
metapneumonoviru
hmpv
human
coronaviru
strain
identifi
virusposit
patient
sever
symptom
baselin
assay
score
appear
highest
patient
supplement
tabl
sever
symptom
total
durat
studi
assess
use
score
auc
maximum
score
sum
daili
score
calcul
per
individu
estim
sever
symptom
followup
period
use
data
particip
averag
auc
valu
total
score
appear
lower
intervent
compar
placebo
group
statist
signific
extent
respect
median
cf
cf
averag
maximum
score
min
max
min
max
intervent
control
group
respect
boxplot
total
score
day
group
present
fig
subject
fig
symptomat
patient
statist
signific
differ
comparison
daili
score
placebo
intervent
group
observ
use
multipl
linear
regress
logtransform
auc
treatment
possibl
predictor
variabl
treatment
found
significantli
affect
ln
auc
ci
adjust
age
ci
bmi
ci
gender
ci
presenc
chronic
ill
ci
baselin
crplevel
ci
treatmentvir
statu
interact
found
distribut
daili
score
virusposit
intervent
control
group
patient
depict
fig
administr
cretan
aromat
plant
extract
virusposit
patient
modifi
total
score
statist
signific
extent
although
lower
score
identifi
intervent
group
compar
placebo
group
median
min
max
cf
min
max
averag
auc
score
also
found
differ
statist
signific
extent
although
lower
score
seen
intervent
group
median
compar
control
group
median
averag
maximum
score
possibl
min
max
min
max
intervent
control
group
respect
use
discretetim
hazard
model
complet
data
set
risk
symptom
cessat
appear
higher
intervent
group
hazard
ratio
hr
ci
adjust
age
gender
similar
result
found
analysi
restrict
virusposit
patient
hr
ci
probabl
cessat
symptom
per
day
present
fig
b
total
sampl
virusposit
patient
respect
trend
toward
higher
albeit
nonstatist
signific
probabl
symptom
cessat
intervent
group
seen
seventi
percent
patient
placebo
group
cessat
symptom
time
final
consult
respect
proport
intervent
group
final
symptom
amelior
consid
per
viru
infect
fig
fit
curv
logist
equat
fig
permit
us
evalu
time
day
amelior
symptom
quantifi
questionnair
despit
small
number
patient
becom
evid
signific
amelior
day
observ
decreas
object
symptom
diseas
patient
baselin
proport
patient
elev
crp
level
similar
group
intervent
placebo
group
respect
followup
respect
proport
intervent
group
placebo
group
intervent
group
patient
initi
elev
crp
level
low
crp
level
followup
compar
patient
placebo
group
ci
percentag
unit
differ
favor
intervent
treatment
calcul
within
group
chang
proport
patient
consist
elev
crp
statist
signific
intervent
placebo
group
respect
detail
present
supplement
tabl
fig
virusposit
group
normal
crp
valu
also
occur
preferenti
intervent
group
fig
supplement
tabl
baselin
proport
patient
elev
crp
level
ident
group
followup
respect
proport
intervent
group
placebo
group
analysi
restrict
within
studi
group
statist
signific
reduct
number
proport
patient
consist
elev
crp
level
found
within
intervent
group
calcul
number
need
treat
nnt
found
treat
subject
whole
group
see
one
symptom
ceas
day
followup
correspond
number
ntt
analyz
data
virusposit
subject
day
final
day
particip
patient
ask
report
possibl
advers
effect
six
complet
studi
report
advers
effect
three
receiv
cretan
aromat
plant
intervent
treatment
three
particip
femal
respect
age
year
old
one
report
frequent
urin
second
report
mild
abdomin
pain
left
upper
quadrant
one
day
third
particip
report
rash
arm
present
three
day
chang
hepat
renal
function
observ
evidenc
sgotsgpt
creatinin
level
respect
therefor
conclud
administr
herbal
extract
least
durat
intervent
safe
much
research
antivir
especi
antiinfluenza
activ
varieti
medicin
plant
worldwid
either
vitro
report
reduct
viral
cytopath
effect
vivo
main
countri
vivo
research
conduct
china
chines
patent
medicin
recip
report
tang
et
al
interest
effect
herbal
remedi
treat
prevent
influenza
influenzalik
ill
acknowledg
howev
systemat
review
perform
databas
report
tabl
present
e
show
time
day
half
encod
symptom
reliev
control
intervent
group
accord
viru
found
day
data
calcul
logist
fit
curv
present
ad
rct
conclud
major
perform
studi
concern
small
group
assay
question
methodolog
report
clinic
irrelev
effect
guo
et
al
anoth
systemat
review
wu
et
al
search
evid
cochran
systemat
review
effect
tradit
chines
medicin
herb
treat
acut
respiratori
infect
came
similar
conclus
author
also
report
lack
qualiti
research
trial
presenc
certain
bias
impact
studi
valid
wu
et
al
recent
chines
rct
wang
et
al
describ
mean
symptom
popul
score
well
number
recov
patient
primari
endpoint
treat
influenza
patient
one
secondari
endpoint
includ
time
requir
allevi
fever
sever
clinic
symptom
wang
et
al
random
clinic
trial
compar
essentialoil
extract
three
cretan
aromat
plant
placebo
main
find
plant
extract
show
statist
signific
benefit
harm
patient
upper
respiratori
ill
caus
although
slight
albeit
nonsignific
amelior
symptom
detect
treat
patient
evid
virusposit
patient
detail
follow
primari
secondari
endpoint
trial
proport
patient
present
symptomfre
day
seven
higher
intervent
control
group
result
close
statist
signific
interestingli
spite
small
number
patient
favor
effect
found
subgroup
influenzainfect
patient
b
proport
patient
whose
crp
level
normal
end
followup
period
signific
intervent
within
placebo
group
addit
found
number
need
treat
nnt
total
popul
decreas
virusposit
popul
mean
least
one
six
virusposit
patient
receiv
benefici
effect
prepar
two
key
issu
taken
consider
prior
safe
conclus
effect
cretan
extract
popul
definit
common
cold
studi
base
jackson
score
base
subject
assess
could
potenti
introduc
select
bia
certain
extent
noninfecti
diseas
includ
studi
sampl
may
explain
high
number
patient
without
virusinfect
result
sampl
size
far
lower
requir
detect
mediumlarg
effect
sizese
method
possibl
inclus
noninfecti
diseas
could
serious
affect
design
studi
assum
high
proport
patient
viru
infect
primari
endpoint
trial
also
base
selfreport
symptom
known
subject
selfassess
might
also
anoth
potenti
sourc
bia
furthermor
selfheal
natur
diseas
small
durat
symptom
present
addit
difficulti
exploit
data
report
provid
clinic
data
without
attempt
deciph
underli
mechan
action
explain
antivir
properti
prepar
howev
preliminari
data
suggest
direct
vitro
antivir
action
prepar
recent
review
highlight
use
certain
herbal
extract
rich
polyphenol
could
play
import
role
control
viru
outbreak
allevi
symptom
hudson
actual
process
delin
direct
antivir
action
prepar
well
specif
constitu
detect
nmr
analysi
although
strongli
believ
benefici
effect
might
attribut
combin
effect
one
constitu
previous
report
case
wine
extract
kampa
et
al
present
studi
first
rct
subject
random
success
creat
compar
baselin
group
term
diseas
preval
demograph
anthropometr
laboratori
biochem
hematolog
immunolog
data
addit
proport
patient
complet
studi
high
howev
certain
limit
need
consid
interpret
result
sampl
limit
size
particip
becom
even
smaller
focuss
patient
document
viral
infect
even
subsampl
viru
posit
patient
sampl
heterogen
sever
type
virus
identifi
howev
effect
extract
might
underestim
sinc
sampl
subject
virusdocu
infect
provid
enough
statist
power
respond
question
potenc
prepar
larg
spectrum
common
cold
influenza
virus
address
laboratori
estim
potenc
prepar
virallyinfect
cell
investig
larger
analysi
permit
collect
significantli
higher
number
virusinfect
patient
use
herb
extens
diffus
among
local
cultur
repres
timelin
ancient
modern
tradit
tradit
cultur
creat
ideal
synergi
engag
pharmaceut
industri
toward
innov
herbalori
research
possibl
new
product
howev
main
intent
introduc
promot
research
base
indigen
knowledg
european
region
flora
especi
island
crete
consid
herbarium
mediterranean
flora
cours
suggest
health
practition
replac
exist
guidelin
use
antivir
treatment
influenza
viru
although
use
specif
antivir
agent
recent
critic
suggest
combin
use
antivir
drug
herbal
extract
may
lead
unwant
drugherb
interact
yang
et
al
studi
find
arriv
time
much
critic
publish
effect
neuraminidas
inhibitor
jefferson
et
al
advers
effect
report
studi
group
inde
current
laboratori
data
suggest
prepar
effect
broad
spectrum
virus
dose
similar
higher
report
compar
placebo
essentialoil
extract
three
cretan
aromat
plant
provid
detect
statist
signific
benefit
harm
patient
upper
respiratori
ill
although
descript
differ
identifi
favor
direct
mainli
virusposit
popul
gener
rct
studi
provid
promis
new
data
field
use
aromat
plant
therapeut
potenti
antivir
therapeut
call
addit
basic
intervent
research
either
prevent
treatment
common
cold
influenza
larger
group
patient
studi
support
unrestrict
grant
grant
olvo
sa
compani
interfer
design
execut
studi
result
present
repres
opinion
author
establish
standard
strictli
follow
univers
crete
special
account
research
elk
